Broad spectrum ?-lactamase inhibitors employing a trojan horse mechanism to rescue ?-lactams against multidrug-resistant pseudomonas aeruginosa
Ended Project Grant Awarded Last action
- Award ID
- R44AI170331
- Recipient
-
Venatorx Pharmaceuticals Inc. UEI MBBKNBU5DCC6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,965,907
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- Pennsylvania, USA
Award details come from USAspending.gov.
Description
- Abstract
- Evolution of multiple resistance mechanisms from extensive use of antibiotics has eroded the efficacy of one of the most important classes of antibiotics, the SS-lactams. The situation is particularly dire in non-fermenting gram-negative pathogens such as pseudomonas aeruginosa, where not only SS-lactamase enzymes (i.e., PDC, per, and VIM) drive resistance but the outer membrane in concert with efflux serves as a formidable barrier to antibiotic entry. This 3-year sbir direct-to-phase II application centers on completing the lead optimization of a unique catechol-conjugated SS-lactamase inhibitor (CC-BLI) series able to take advantage of facilitated entry and offering an unprecedented level of activity against multidrug-resistant (MDR) pseudomonas when combined with ceftolozane (currently marketed as zerbaxa®). The commercial presentation of zerbaxa® is intravenous ceftolozane combined with the legacy SS-lactamase inhibitor tazobactam; however, tazobactam fails to protect ceftolozane from ambler class c pseudomonas-derived cephalosporinases (PDC), as well as class a (KPC), b (VIM and NDM), and d (OXA) carbapenemase. In addition to enhanced entry the CC-BLI series has activity against serine and metallo-SS-lactamase enzymes including those that hydrolyze carbapenems. At the completion of lead optimization, the resulting preclinical development candidate will be paired with ceftolozane (TOL), which best supports the potent activity in p. Aeruginosa. This candidate TOL/CC-BLI combination will be advanced through non-GLP toxicology activities and eventually to IND filing and approval. Ultimately, IT is envisioned that this new combination product will provide a unique clinical option for empiric therapy of MDR non-fermenter infections in the hospital general ward and ICU and as a second-line therapy for susceptible organisms.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$34,093 | |
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Amendment | $1,000,000 | |
| Original award | $1,000,000 |
Quick answers
Who received award R44AI170331?
R44AI170331 was awarded to Venatorx Pharmaceuticals Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 10, 2022.
How much is award R44AI170331 worth?
$5,965,907 has been obligated on R44AI170331.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award